Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Beijing Biostar Pharmaceuticals Co., Ltd. Class H (2563) Stock Price & Analysis

0 Followers

2563 Stock Chart & Stats

HK$3.32HK$0.02(0.61%)
At close: 4:00 PM GMT+8
HK$3.5HK$4HK$4.5Aug 18Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 3.32 - HKD 3.50
52-Week Range
HKD 2.50 - HKD 5.25
Previous Close
HKD 3.30
Volume
N/A
Average Volume (3M)
10.87K
Market Cap
HKD 1.36B
Enterprise Value
HKD 843.39M
Total Cash (Recent Filing)
HKD 516.22M
Total Debt (Recent Filing)
HKD 1.61M
Price to Earnings (P/E)
―
Beta
0.25
Next Earnings
Jul 05, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Very Low Leverage

Debt-to-equity of roughly 0.3% in 2025 indicates minimal reliance on borrowing and limits solvency pressure. This gives the company more financial flexibility than a highly levered peer, although it does not by itself offset losses or cash consumption.

High Gross Margins

Gross margin was about 92% in 2025 and has generally ranged from roughly 70% to 94%. Such product-level economics suggest the medicines can generate substantial gross profit per unit, providing a potentially strong base for improvement if operating costs become better aligned with revenue.

Sizable Equity Base

A sizable equity base provides a financial cushion alongside the company’s very low debt burden. This can support continued operations and development through periods of pressure, although the decline in equity over time shows that persistent losses are eroding part of that cushion.

Bears Say

Persistent Heavy Losses

Large operating and net losses are reported every year shown, with 2025 net margin around -394%. This indicates that operating expenses remain far above the gross profit generated, making a durable path to profitability the central business challenge and potentially limiting internally funded investment.

Recurring Cash Burn

Operating cash flow was negative every year provided, reaching about -169M in 2025, while free cash flow was about -175M. Persistent cash burn can consume available equity funding and restrict the company’s ability to sustain development or expand without additional financing.

Sharp Revenue Decline

Revenue fell about 51% in 2025 versus 2024 after a strong 2023 rebound and only modest 2024 growth. This unstable top-line trajectory makes fixed operating costs harder to absorb, reduces visibility into scale benefits, and complicates planning for future investment.

Beijing Biostar Pharmaceuticals Co., Ltd. Class H News

2563 FAQ

What was Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price range in the past 12 months?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H lowest stock price was HK$2.50 and its highest was HK$5.25 in the past 12 months.
What is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s market cap?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s market cap is HK$1.36B.
When is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s earnings last quarter?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H released its earnings results on Aug 26, 2026. The company reported -HK$0.083 earnings per share for the quarter.
Is Beijing Biostar Pharmaceuticals Co., Ltd. Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Beijing Biostar Pharmaceuticals Co., Ltd. Class H pay dividends?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H does not currently pay dividends.
What is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s EPS estimate?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Biostar Pharmaceuticals Co., Ltd. Class H have?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H has 389,588,000 shares outstanding.
What happened to Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price movement after its last earnings report?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H reported an EPS of -HK$0.083 in its last earnings report. Following the earnings report the stock price went up 3.714%.
Which hedge fund is a major shareholder of Beijing Biostar Pharmaceuticals Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2563
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology